Introduction {#S0001}
============

Gastric cancer (GC) represents the second leading cause of death among all cancer types and caused 782,685 deaths worldwide in 2018.[@CIT0001] Currently, the incidence of GC has significantly increased, with about 1,033,701 new cases every year.[@CIT0001] China has a high risk for GC, and the new cases of GC in this region account for about 43% in the world.[@CIT0002] Despite the improvement of diagnostic and therapeutic methods in the past decades,[@CIT0003],[@CIT0004] the prognosis of GC is still poor (5-year survival rate \<20%) since it is mostly diagnosed at advanced stage.[@CIT0003],[@CIT0004] Therefore, effective therapeutic approaches should be developed.

Traditional Chinese medicine has an extensive history and has been more widely used as an effective adjuvant drug for cancer treatment.[@CIT0005]--[@CIT0010] Cinobufotalin is a cardiotonic steroid or bufotalin, which is extracted from the skin secretion of the giant toad.[@CIT0010]--[@CIT0014] Many in vitro studies have shown that cinobufotalin has antitumor activity and enhanced chemotherapeutic effect.[@CIT0007],[@CIT0010],[@CIT0013],[@CIT0014] Cinobufotalin can inhibit the growth and metastasis of the tumor by inhibiting the expression of vascular endothelial growth factor and epidermal growth factor receptor.[@CIT0015] Additionally, it can also kill tumor cells by inducing non-apoptotic death possibly depending on cyclophilin-D involved pathway.[@CIT0012]

Several studies have indicated that chemotherapy combined with cinobufotalin exhibits more prominent therapeutic effects than chemotherapy alone for advanced GC.[@CIT0016]--[@CIT0042] Despite the intensive clinical studies using cinobufotalin and chemotherapy combined therapy in treating GC, its clinical efficacy and safety have not been systematically evaluated. In this study, we conducted a meta-analysis to investigate the treatment efficacy and safety of chemotherapy combined with cinobufotalin in comparison with chemotherapy alone for advanced GC to provide scientific reference for the design of future clinical trials.

Materials and methods {#S0002}
=====================

Search strategy and selection criteria {#S0002-S2001}
--------------------------------------

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Cochrane Handbook. Original articles were searched across eight electronic databases, including Cochrane Library, Web of Science, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biological Medicine Database (CBM), Wanfang database and Chinese Scientific Journal Database (VIP) before September 2018, with key terms "huachansu" or "cinobufotalin," "cinobufacini," or "cinobufagin" combined with "gastric carcinoma" or "gastric cancer." No language limits were applied.

Selection Criteria: The inclusion criteria were as follows: (1) controlled trials concerning advanced GC patients, (2) literature comparing the clinical outcomes of chemotherapy plus cinobufotalin adjuvant therapy (experimental group) with chemotherapy treatments alone (control group) and (3) articles involving more than 40 GC patients. On the other hand, the exclusion criteria were as follows: (1) non-contrast articles, case studies and review papers and (2) patients with mixed malignancies.

Data extraction and quality assessment {#S0002-S2002}
--------------------------------------

Data were independently extracted by two investigators (Sun HL, and Bai MH) following the same inclusion criteria; disagreements were adjudicated by the third reviewer (Liu DL). The extracted characteristics were summarized as follows: (I) first author's names, (II) years of publication, (III) study locations, (IV) tumor stages, (V) Karnofsky Performance Score (KPS), (VI) number of cases, (VII) patient ages, (VIII) study parameter types, (IX) therapeutic regimens, (X) enrollment period and (XI) dosage of cinobufotalin. The included trial's quality was evaluated according to the Cochrane Handbook.[@CIT0043]

Outcome definition {#S0002-S2003}
------------------

Clinical responses include treatment efficacy, quality of life (QoL) and adverse events. Treatment efficacy was assessed in terms of the overall survival rates (OS rates, defined as the length of time from the start of treatment to death from any cause), complete response (CR) rates, partial response (PR) rates, stable disease (SD) rates, progressive disease (PD) rates, overall response rates (ORRs, ORR=CR + PR) and disease control rates (DCRs, DCR=CR + PR + SD). Patients' QoL was evaluated using QoL improved rate (QIR), KPS and pain relief rate (PRR). Adverse events including nausea and vomiting, diarrhea, leucopenia, thrombocytopenia, hepatotoxicity, nephrotoxicity, oral mucositis, alopecia, hand-foot syndrome, anemia, gastrointestinal adverse effects, peripheral neurotoxicity, neutropenia and myelosuppression were also assessed.

Statistical analysis {#S0002-S2004}
--------------------

RevMan 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 13.0 (Stata Corp., College Station, TX, USA) software were the main statistical analysis tools in this study. *P*\<0.05 was considered statistically significant. Analysis model was determined by heterogeneity among studies assessed using Cochran's Q test, and publication bias was analyzed using Begg's and Egger's regression asymmetry tests and presented using funnel plots.[@CIT0044] *I^2^*\<50% or *P*\>0.1 indicated that the studies were homogenous. Treatment effects were mainly represented by odds ratio (OR) presented with a 95% confidence interval (CI). Pooled analysis with publication bias determined that trim and fill method would be applied to coordinate the estimates of unpublished studies, and the adjusted results were compared with the original pooled OR.[@CIT0045] Sensitivity analysis was performed to evaluate the impact of different therapeutic regimens, drug forms of cinobufotalin, sample sizes and research types on clinical efficacy.

Results {#S0003}
=======

Search results {#S0003-S2001}
--------------

A total of 493 articles were identified and initially retrieved, and 275 papers were excluded due to duplication. After title and abstract review, 163 articles were further excluded because they did not include clinical trials (n=127) and were unrelated studies (n=34) or published before 2000 (n=2), leaving 55 studies as potentially relevant. After detailed assessment of full texts, articles without control group (n=8), studies with case reports (n=6), reviews or meta-analysis (n=5), and trials with insufficient data (n=9) were excluded. Finally, 27 trials[@CIT0016]--[@CIT0042] involving 1,939 advanced GC patients were included in this analysis ([Figure 1](#F0001){ref-type="fig"}).Figure 1Flow diagram of the selection process.

Patient characteristics {#S0003-S2002}
-----------------------

After selection, all included studies were performed in different medical centers of China since 2000. In total, 972 advanced GC patients were treated with chemotherapy in combination with cinobufotalin adjuvant therapy, while 967 patients were treated with chemotherapy alone. Detailed information of the involved studies and GC patients is shown in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}.Table 1Clinical information from the eligible trials in the meta-analysisIncluded studiesNationTumor stageKPSPatients Con/ExpAge (year)Parameter typesConExpCha XT (2016)[@CIT0016]ChinaND\>7020/20NDNDORR, DCR, AEChen GF (2012)[@CIT0017]ChinaIVND86/6271.8±18.6 (mean)73.1±22.3 (mean)ORR, DCR, QoL, AEChen HM(2009)[@CIT0018]ChinaIII--IVKPS≥6033/3449.6 (median)50.6 (median)ORR, DCRCui P (2009)[@CIT0019]ChinaND65 (mean)23/32NDNDORR, DCR, QoL, AEGuo CJ (2011)[@CIT0020]ChinaIV≥5043/43NDNDORR, DCR, QoLGuo XY (2013)[@CIT0021]ChinaIII--IV≥6538/4264.8±3.7 (mean)66.4±4.2 (mean)ORR, DCR, QoLHuang Q (2014)[@CIT0022]ChinaND≥6020/2655.8±4.9 (mean)57.4±5.6 (mean)ORR, DCR, QoLLi W (2016)[@CIT0023]ChinaNDND74/7666.8±1.4 (mean)66.6±1.5 (mean)ORR, DCR, AELi YX (2012)[@CIT0024]ChinaNDND74/74NDNDORR, DCR, QoL, AELu B (2016)[@CIT0025]ChinaND\>6030/3074.8±6.2 (mean)73.7±5.1 (mean)ORR, DCR, QoL, AELu CH (2014)[@CIT0026]ChinaND71 (mean)31/31NDNDORR, DCRTian B (2012)[@CIT0027]ChinaIII--IVKPS\>6022/23NDNDORR, DCR, AEWang F (2014)[@CIT0028]ChinaNDND58/5858.8 (mean)58.4 (mean)ORR, DCR, QoL, AEWang WM (2010)[@CIT0029]ChinaND\>6023/20NDNDORR, DCR, AEWang YH (2009)[@CIT0030]ChinaIII--IV\>6032/36NDNDORR, DCR, AEWang ZF (2012)[@CIT0031]ChinaND\>6024/2459.1 (median)58.7 (median)ORR, DCR, QoLXiao XN (2018)[@CIT0032]ChinaIII--IV58 (mean)31/34NDNDORR, DCR, QoL, AEXu DM (2015)[@CIT0033]ChinaND\>6030/3065.0±3.9 (mean)66.3±4.6 (mean)ORR, DCR, QoL, AEXu YM (2016)[@CIT0034]ChinaND≥6030/3049.9 (median)45.8 (median)ORR, DCR, QoL, AEYang B (2017)[@CIT0035]ChinaND\>6034/3453 (mean)51 (mean)ORR, DCRYang F (2018)[@CIT0036]ChinaNDND25/2550 (median)54 (median)ORR, DCR, QoL, AEZhang CW (2001)[@CIT0037]ChinaIII--IV\>7032/3566 (median)64 (median)ORR, DCR, AEZhang RG (2004)[@CIT0038]ChinaIV≥4043/4348 (median)49 (median)OS, ORR, DCR, AEZhang Y (2005)[@CIT0039]ChinaIV≥4029/2854 (median)57 (median)OS, ORR, AEZheng YL (2007)[@CIT0040]ChinaIII--IV68 (mean)20/20NDNDOS, QoLZhu WK (2012)[@CIT0041]ChinaIII--IV≥7032/3262.8 (mean)61.7 (mean)ORR, DCR, QoL, AEZou HP (2012)[@CIT0042]ChinaIII--IVND30/3056.5 (median)59.1 (median)ORR, DCR, AE[^1] Table 2Information on cinobufotalin combined with chemotherapyIncluded studiesTherapeutic regimenEnrollment PeriodDosage of cinobufotalinExperimental groupControl groupCha XT (2016)[@CIT0016]Oxaliplatin+Tegafur+CF/SF+Cinobufotalin^a^Oxaliplatin+Tegafur+CF/SFJanuary 2013--March 2016750 mg/time, 3 times/dayChen GF (2012)[@CIT0017]Capecitabine+Cinobufotalin^b^CapecitabineOctober 2006--October 201010 ml/time, 3 times/dayChen HM (2009)[@CIT0018]Paclitaxel+Cisplatin+5-Fu+Cinobufotalin^b^Paclitaxel+Cisplatin+5-FuOctober 2005--December 200730 ml/time, 1 time/dayCui P (2009)[@CIT0019]FOLFOX+Cinobufotalin^b^FOLFOX2004--200630 ml/time, 1 time/dayGuo CJ (2011)[@CIT0020]Docetaxel+Cinobufotalin^b^DocetaxelMarch 2005--March 201020 ml/time, 1 time/dayGuo XY (2013)[@CIT0021]FOLFOX+Cinobufotalin^c^FOLFOXJanuary 2009--May 20101200 mg/time, 4 times/dayHuang Q (2014)[@CIT0022]XELOX+Cinobufotalin^b^XELOXAugust 2009--August 201350 ml/time, 1 time/dayLi W (2016)[@CIT0023]Capecitabine+Cinobufotalin^b^CapecitabineJanuary 2012--January 201510-20 ml/time, 1 time/dayLi YX (2012)[@CIT0024]Capecitabine+Cinobufotalin^b^CapecitabineJanuary 2006--July 201110 ml/time, 1 time/dayLu B (2016)[@CIT0025]Capecitabine+Cinobufotalin^a^CapecitabineJanuary 2010--December 2012500 mg/time, 3 times/day,Lu CH (2014)[@CIT0026]FOLFOX+Cinobufotalin^b^FOLFOX2009--201320 ml/time, 1 time/dayTian B (2012)[@CIT0027]FOLFOX+Cinobufotalin^b^FOLFOX2004--200630 ml/time, 1 time/dayWang F (2014)[@CIT0028]Cisplatin+5-Fu+Cinobufotalin^a^Cisplatin+5-FuND500 mg/time, 3 times/day,Wang WM (2010)[@CIT0029]S-1+Cinobufotalin^a^S-1October 2011--October 2013500 mg, 3 times/dayWang YH (2009)[@CIT0030]FOLFOX+Cinobufotalin^b^FOLFOXDecember 2004--May 200810-20 ml/time, 1 time/dayWang ZF (2012)[@CIT0031]FOLFOX+Cinobufotalin^b^FOLFOXDecember 2003--May 200820 ml/time, 1 time/dayXiao XN (2018)[@CIT0032]FOLFOX+Cinobufotalin^b^FOLFOXJanuary 2008--December 201010-20 ml/time, 1 time/dayXu DM (2015)[@CIT0033]Docetaxel+Cisplatin+Cinobufotalin^b^Docetaxel+Cisplatin2013--201620 ml/time, 1 time/dayXu YM (2016)[@CIT0034]Capecitabine+Cinobufotalin^b^CapecitabineJune 2010--June 201120 ml/time, 1 time/dayYang B (2017)[@CIT0035]FOLFOX+Cinobufotalin^a^FOLFOXJanuary 2014--April 2015750 mg/time, 3 times/day,Yang F (2018)[@CIT0036]XELOX+Cinobufotalin^b^XELOXJanuary 2015--June 201720 ml/time, 1 time/dayZhang CW (2001)[@CIT0037]EOF+Cinobufotalin^a^EOFMay 2014--May 2015200-500 mg/time, 3 times/dayZhang RG (2004)[@CIT0038]Etoposide+Leucovorin+5-Fu+Cinobufotalin^b^Etoposide+Leucovorin+5-FuMarch 1999--December 200020 ml/time, 1 time/dayZhang Y (2005)[@CIT0039]HCPT+CF+5-Fu+Cinobufotalin^b^HCPT+CF+5-FuJuly 1998--June 200320 ml/time, 1 time/dayZheng YL (2007)[@CIT0040]FOLFOX+Cinobufotalin^b^FOLFOXMarch 2002--February 200350 ml/time, 1 time/dayZhu WK (2012)[@CIT0041]Oxaliplatin+Capecitabine+Cinobufotalin^b^Oxaliplatin+CapecitabineMarch 2010--MArch 201130 ml/time, 1 time/dayZou HP (2012)[@CIT0042]EOF+Cinobufotalin^b^EOFMay 2008--May 201120 ml/time, 1 time/day[^2][^3]

Quality assessment {#S0003-S2003}
------------------

The assessment of bias risk is shown in [Figure 2](#F0002){ref-type="fig"}. A total of 24 studies were determined as having low risk, and the remaining 3 studies were not true randomized controlled trials. All included trials did not provide clear description of performance and detection risks. The attrition risks of involved trials were low; 9 trials were considered as having unclear risk owing to selective reporting.Figure 2(**A**) Risk of bias summary: review of authors' judgments about each risk of bias item for included studies. (**B**) Risk of bias graph: review of authors' judgments about each risk of bias item presented as percentages across all included studies. Each color represents a different level of bias: red for high-risk, green for low-risk and yellow for unclear-risk of bias.

Therapeutic efficacy assessment {#S0003-S2004}
-------------------------------

As shown in [Figures 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}, [Figure S1](#SF0001) and [Table 3](#T0003){ref-type="table"}, the pooled results showed that patients who underwent combined therapy had significantly improved CR, PR, ORR and DCR (CR, OR =1.69, 95% CI =1.11--2.57, *P*=0.01; PR, OR =1.69, 95% CI =1.38--2.08, *P*\<0.00001; ORR, OR =1.88, 95% CI =1.54--2.31, *P*\<0.00001; DCR, OR =2.05, 95% CI =1.63--2.58, *P*\<0.00001) and significantly decreased PD (OR =0.49, 95% CI =0.39--0.61, *P*\<0.00001), whereas SD and 6- and 12-months OS rates had no significant differences in patients who received chemotherapy alone (SD, OR =0.94, 95% CI =0.76--1.15, *P*=0.53; 6-months OS, OR =1.49, 95% CI =0.81--2.74, *P*=0.20; 12-months OS, OR =1.35, 95% CI =0.64--2.86, *P*=0.43). Fixed effect models were used to analyze OR rate because of low heterogeneity.Table 3Comparison of CR, PR, SD, PD, ORR and DCR between the experimental and control groupParameterExperimental groupControl groupAnalysis methodHeterogeneityOdds Ratio (OR)95% CI*P*-valueNo. patients (n)No. patients (n)I[@CIT0002] (%)*P*-valueCR924917Fixed01.001.691.11 to 2.570.01PR924917Fixed00.951.691.38 to 2.08\<0.00001SD924917Fixed00.620.940.76 to 1.150.53PD924917Fixed00.860.490.39 to 0.61\<0.00001ORR952946Fixed00.961.881.54 to 2.31\<0.00001DCR924917Fixed00.862.051.63 to 2.58\<0.00001[^4] Figure 3Forest plot of the comparison of 6-months (**A**) and 12-months (**B**) overall survival (OS) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects meta-analysis model (Mantel--Haenszel method) was used.Figure 4Forest plot of the comparison of overall response rate (ORR, **A**) and disease control rate (DCR, **B**) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects meta-analysis model (Mantel--Haenszel method) was used.

Quality of life assessment {#S0003-S2005}
--------------------------

QoL was evaluated in this analysis. Result showed that QoL of patients in the combined group was significantly better than that of the control group, indicated by increased QIR, KPS and PRR ([Figure 5](#F0005){ref-type="fig"}, QIR, OR =2.39, 95% CI =1.81--3.15, *P*\<0.00001; KPS, OR =7.00, 95% CI =2.25--11.75, *P*=0.004; PRR, OR =4.06, 95% CI =2.24--7.35, *P*\<0.00001).Figure 5Forest plot of the comparison of quality of life improved rate (QIR, **A**), karnofsky performance score (KPS, **B**) and pain relief rate (PRR, **C**) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects meta-analysis model (Mantel--Haenszel method) was used.

Adverse event assessment {#S0003-S2006}
------------------------

As shown in [Table 4](#T0004){ref-type="table"} and [Figure S2](#SF0002A), patients treated with cinobufotalin and chemotherapy combined therapy showed lower incidences of nausea and vomiting, diarrhea, leucopenia, hand-foot syndrome, anemia, gastrointestinal side effects and peripheral neurotoxicity (nausea and vomiting, OR =0.55, 95% CI =0.41--0.74, *P*\<0.0001; diarrhea, OR =0.65, 95% CI =0.46--0.90, *P*=0.010; leucopenia, OR =0.62, 95% CI =0.47--0.82, *P=*0.0008; hand-foot syndrome, OR =0.57, 95% CI =0.41--0.79, *P*=0.0007; anemia, OR =0.69, 95% CI =0.48--0.99, *P*=0.05; gastrointestinal side effects, OR =0.56, 95% CI =0.32--1.00, *P*=0.05; peripheral neurotoxicity, OR =0.32, 95% CI =0.20--0.50, *P*\<0.00001), whereas analysis on thrombocytopenia, hepatotoxicity, nephrotoxicity, oral mucositis, alopecia, neutropenia and myelosuppression (thrombocytopenia, OR =0.69, 95% CI =0.44--1.11, *P*=0.13; hepatotoxicity, OR =0.53, 95% CI =0.24--1.16, *P*=0.11; nephrotoxicity, OR =0.56, 95% CI =0.16--1.95, *P*=0.36; oral mucositis, OR =0.62, 95% CI =0.28--1.34, *P*=0.22; alopecia, OR =0.61, 95% CI =0.24--1.56, *P*=0.30; neutropenia, OR =0.45, 95% CI =0.14 −1.42, *P*=0.17; myelosuppression, OR =0.38, 95% CI =0.08--1.84, *P*=0.23) did not differ significantly between the two groups.Table 4Comparison of adverse events between the experimental and control groupAdverse eventsExperimental groupControl groupAnalysis methodHeterogeneityOdds Ratio (OR)95% CI*P*-valueNo. of patients (n)No. of patients (n)I[@CIT0002] (%)*P*-value**Nausea, vomiting**452437Fixed370.090.550.41 to 0.74\<0.0001Nausea, vomiting I+II292279Fixed00.500.830.59 to 1.160.27Nausea, vomiting III+IV292279Fixed40.410.410.23 to 0.750.003**Diarrhea**395379Fixed00.880.650.46 to 0.900.010Diarrhea I+II235221Fixed00.690.840.56 to 1.270.41Diarrhea III+IV235221Fixed01.000.270.10 to 0.750.01**Leucopenia**420429Fixed340.130.620.47 to 0.820.0008Leucopenia I+II250238Fixed00.860.570.39 to 0.830.003Leucopenia III+IV250238Fixed00.770.360.17 to 0.750.007**Thrombocytopenia**178178Fixed00.810.690.44 to 1.110.13Thrombocytopenia I+II178178Fixed00.840.700.43 to 1.130.14Thrombocytopenia III+IV178178Fixed00.830.910.39 to 2.140.83**Hepatotoxicity**193193Random560.040.530.24 to 1.160.11Hepatotoxicity I+II193193Fixed260.240.610.38 to 0.970.04Hepatotoxicity III+IV193193Fixed00.700.140.02 to 0.810.03**Nephrotoxicity**117107Fixed00.770.560.16 to 1.950.36Nephrotoxicity I+II117107Fixed00.540.630.16 to 2.460.51Nephrotoxicity III+IV117107Fixed0.320.01 to 8.240.49**Oral mucositis**235233Random640.0100.620.28 to 1.340.22Oral mucositis I+II179178Fixed440.131.080.68 to 1.720.74Oral mucositis III+IV179178Fixed00.580.540.15 to 1.960.35**Alopecia**133130Fixed00.580.610.24 to 1.560.30Alopecia I+II133130Fixed00.930.930.48 to 1.810.83Alopecia III+IV133130Fixed00.970.720.30 to 1.750.47**Hand foot syndrome**334356Fixed00.520.570.41 to 0.790.0007Hand foot syndrome I+II9292Fixed120.320.640.33 to 1.240.18Hand foot syndrome III+IV9292Fixed0.480.04 to 5.630.56**Anemia**292291Fixed00.910.690.48 to 0.990.05Anemia I+II186187Fixed00.650.920.60 to 1.420.71Anemia III+IV186187Fixed00.870.340.12 to 0.960.04**Gastrointestinal adverse effects**277295Random570.040.560.32 to 1.000.05Gastrointestinal adverse effects I+II7172Fixed00.750.710.35 to 1.420.33Gastrointestinal adverse effects III+IV7172Fixed0.390.09 to 1.600.19**Peripheral neurotoxicity**265263Fixed00.590.320.20 to 0.50\<0.00001Peripheral neurotoxicity I+II103104Fixed290.240.520.26 to 1.030.06Peripheral neurotoxicity III+IV103104Fixed00.530.580.21 to 1.630.30**Neutropenia**5555Fixed00.980.450.14 to 1.420.17Neutropenia I+II5555Fixed00.350.930.44 to 1.960.85Neutropenia III+IV5555Fixed00.400.730.34 to 1.590.43**Myelosuppression**9490Random800.030.380.08 to 1.840.23Myelosuppression I+II5858Fixed1.090.48 to 2.490.83Myelosuppression III+IV5858Fixed0.240.03 to 2.190.20[^5]

Publication bias {#S0003-S2007}
----------------

Funnel plots drawn for the studies on primary outcomes (CR, PR, SD, PD, ORR, DCR and adverse events) were approximately symmetrical, which indicated generally controlled publication bias and reliability of our primary conclusions ([Figure 6](#F0006){ref-type="fig"} and [S3](#SF0003)).Figure 6Funnel plot of overall response rate (ORR, **A**), disease control rate (DCR, **B**), quality of life improved rate (QIR, **C**), Nausea and vomiting (**D**), Diarrhea (**E**), Leukopenia (**F**), Anemia (**G**) and neurotoxicity (**H**).Figure S3Funnel plot of percentage of complete response rates (CR, **A**), partial response rates (PR, **B**), stable disease rates (SD, **C**) and progressive disease rates (PD, **D**).

We also assessed publication bias using Begg's and Egger's regression asymmetry tests ([Table 5](#T0005){ref-type="table"}), and PR and leucopenia were found with bias (PR, Begg, 0.038; Egger, 0.015; leucopenia, Begg, 0.003; Egger, \<0.0001). To determine if the bias affects the pooled risk, we conducted a trim and fill analysis. The adjusted OR rate indicated the same trend with the result of the primary analysis (PR \[before, *P*\<0.0001; after, *P*\<0.0001\], leukopenia \[before, *P*=0.0002; after. *P*=0.0002\]), reflecting the reliability of our primary conclusions, except those based on a few number of trials.Table 5Publication bias on therapeutic efficacy indexes (CR, PR, SD, PD, ORR, DCR and QIR) and adverse events indexes (Nausea and vomiting, Diarrhea, Leucopenia, Anemia and Neurotoxicity)Publication BiasTherapeutic efficacyAdverse eventsCRPRSDPDORRDCRQIRNausea and vomitingDiarrheaLeucopeniaAnemiaNeurotoxicity**Begg**0.7420.0380.5130.8700.2800.8700.3040.1610.7550.0030.4541.000**Egger**0.8330.0150.7210.9050.3310.9050.2350.0690.623\<0.00010.5280.894[^6]

Sensitivity analysis {#S0003-S2008}
--------------------

We performed subgroup analysis to explore the source of heterogeneity in ORR and DCR with respect to therapeutic regimens, drug forms of cinobufotalin, sample sizes and research types. As shown in [Table 6](#T0006){ref-type="table"}, our analysis results showed that no significant difference was found between different forms of cinobufotalin, sample sizes and research types. Moreover, cinobufotalin combined with FOLFOX/XELOX/capecitabine chemotherapy regimens was found to be more effective for GC treatment.Table 6Subgroup analyses of ORR and DCR between the experimental and control groupParameterFactors at study levelExperimental group No. of patients (n)Control group No. of patients (n)Analysis methodHeterogeneityOdds Ratio (OR)95% CI*P*-valueI[@CIT0002] (%)*P*-valueORR**Therapeutic regimen**Cinobufotalin+FOLFOX215200Fixed00.991.841.23 to 2.760.003Cinobufotalin+XELOX9286Fixed00.412.431.30 to 4.530.005Cinobufotalin+EOF5555Fixed220.261.930.91 to 4.100.09Cinobufotalin+Capecitabine272294Fixed00.851.981.29 to 3.040.002**Drug form of cinobufotalin**Cinobufotalin capsule186185Fixed90.362.471.54 to 3.980.0002Cinobufotalin injection724723Fixed00.981.781.41 to 2.25\<0.00001**Study sample size**\>60634641Fixed00.672.051.58 to 2.65\<0.00001≤60318305Fixed00.991.641.18 to 2.280.003**Type of control trials**RCT833829Fixed00.961.931.55 to 2.41\<0.00001Overall952946Fixed00.961.881.54 to 2.31\<0.00001DCR**Therapeutic regimen**Cinobufotalin+FOLFOX215200Fixed00.972.261.26 to 4.040.006Cinobufotalin+XELOX9286Fixed00.392.551.24 to 5.230.01Cinobufotalin+EOF5555Fixed00.711.700.52 to 5.570.38Cinobufotalin+Capecitabine272294Fixed00.631.631.11 to 2.380.01**Drug form of cinobufotalin**Cinobufotalin capsule186185Fixed00.492.781.69 to 4.58\<0.0001Cinobufotalin injection696694Fixed00.871.881.45 to 2.45\<0.00001**Study sample size**\>60634641Fixed00.532.211.68 to 2.90\<0.00001≤60290276Fixed00.941.731.13 to 2.640.01**Type of control trials**RCT805800Fixed00.862.161.69 to 2.77\<0.00001Overall924917Fixed00.862.051.63 to 2.58\<0.00001[^7]

Discussion {#S0004}
==========

In view of the limitations of the current chemotherapy for malignancies such as drug resistance and toxic side effects, clinicians have been exploring complementary and alternative medicine treatments to improve patients' survival time or QoL and reduce side effects caused by chemotherapy.[@CIT0006],[@CIT0010],[@CIT0046],[@CIT0047] Traditional Chinese medicine, particularly cinobufotalin, has been clinically applied as an adjuvant therapy for decades.[@CIT0007],[@CIT0010],[@CIT0011] Several studies have been reported that the addition of cinobufotalin could be beneficial to advanced GC patients.[@CIT0016]--[@CIT0042] Even though there was a statistical analysis of published clinical trials, the exact therapeutic effects were still not systematically evaluated because of small sample sizes and different applied protocols in different studies. Therefore, in this analysis, we conducted a wide range of online search according to strict inclusion and exclusion criteria to provide clear and systematical conclusion.

Our meta-analysis revealed that cinobufotalin and chemotherapy combined therapy for GC patients achieved more beneficial effects in comparison with those treated with chemotherapy alone. Combined therapy-treated patients broadly exhibited increased ORR and DCR (*P*\<0.05) and also significantly improved their QoL. These results indicated that using cinobufotalin could improve the curative effects of chemotherapy.

Safety is the top priority of the clinical treatment. One trial[@CIT0007] that was conducted at Fudan University Cancer Hospital showed that cinobufotalin is well tolerated by hepatocellular carcinoma, non-small-cell lung cancer and pancreatic cancer patients (only mild adverse events were observed in cancer patients who received cinobufotalin therapy; no grade III and IV toxicities were observed). Our analysis showed that most of the adverse events caused by chemotherapy, including nausea and vomiting, diarrhea, leucopenia, hand-foot syndrome, anemia, gastrointestinal side effects and peripheral neurotoxicity, were alleviated with cinobufotalin combination therapy (*P*\<0.05). Therefore, cinobufotalin is a safe auxiliary antitumor medicine for GC and can effectively alleviate the adverse events associated with chemotherapy.

The analysis on therapeutic effects may be influenced by several factors. In our study, no difference was found between different drug forms of cinobufotalin, sample sizes and research types. Cinobufotalin combined with FOLFOX/XELOX/capecitabine chemotherapy regimens was more effective for GC treatment ([Table 6](#T0006){ref-type="table"}). However, a comparative analysis of the above-mentioned individual chemotherapy regimens should be performed in the future to rule out the possibility that the therapeutic advantage of cinobufotalin combined with FOLFOX, XELOX or capecitabine is due to the better therapeutic effect of them alone compared to that of EOF. As a summary, recent studies on the impact of these factors on the curative effects of cinobufotalin adjuvant therapy remain insufficient, and hence, further investigations should be performed.

There are some limitations in our analysis. First, although traditional Chinese medicine has been exported to 185 countries and regions, its main markets still remained in Asia.[@CIT0048] As a traditional medicine, cinobufotalin was mainly applied in China, which may bring the unavoidable regional bias and subsequently influence the clinical application of cinobufotalin worldwide. Second, according to the Cochrane Handbook for systematic reviews of interventions, the most appropriate way of summarizing survival outcomes is to use methods of survival analysis and express the intervention effect as a hazard ratio (HR) because this method takes into consideration the time factor and censored participants. However, the included articles that reported the OS rate only provided the survival number and the total number of patients at 6 months and 12 months, and none of them provided HR with 95% CI and Kaplan--Meier survival curves. Therefore, there were insufficient data to perform a statistical analysis using HR, which almost certainly will introduce bias. Third, treatment/medical history is very important in evaluating the efficacy of cinobufotalin-mediated therapy. However, our data were partly extracted from published papers rather than from the original patient records; therefore, analytical bias would possibly exist. Moreover, the therapeutic effects of the combined therapy may be influenced by numerous variables such as dosage of cinobufotalin, tumor stage and patient's age. However, based on currently available literature, there are insufficient data to perform more statistical analysis to evaluate the correlation. We will keep following up with upcoming clinical trials to obtain relevant data when available. Finally, the follow-up durations of the included studies were short, and the long-term efficacy of cinobufotalin for advanced GC remains to be further evaluated.

Conclusion {#S0005}
==========

In summary, this meta-analysis indicated that cinobufotalin and chemotherapy combined therapy was effective in treating advanced GC. Clinical application of cinobufotalin not only evidently improved the therapeutic effects of chemotherapy but also effectively alleviated most of the side effects caused by chemotherapy. However, the long-term efficacy of cinobufotalin-mediated adjuvant therapy for advanced GC still needs methodologically rigorous trials to verify its efficacy.
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Figure S1Forest plot of the comparison of complete response rates (CR, **A**), partial response rates (PR, **B**), stable disease rates (SD, **C**) and progressive disease rates (PD, **D**) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. The fixed-effects meta-analysis model (Mantel--Haenszel method) was used. Figure S2Forest plot of the comparison of adverse effects including nausea and vomiting (**A**), diarrhea (**B**), leukopenia (**C**), thrombocytopenia (**D**), hepatotoxicity (**E**), nephrotoxicity (**F**), oral mucositis (**G**), alopecia (**H**), hand-foot syndrome (**I**), anemia (**J**), gastrointestinal adverse effects (**K**), peripheral neurotoxicity (**L**), neutropenia (**M**) and myelosuppression (**N**) between the experimental and control group. Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. Figure S2(Continued). Figure S2(Continued). Figure S2(Continued).

[^1]: **Notes:** Con, control group (chemotherapy alone group); Exp, experimental group (chemotherapy and cinobufotalin combined group).

    **Abbreviations:** ND, non determined; KPS, karnofsky performance score; ORR, overall response rate; DCR, disease control rate; Qol, quality of life; AE, adverse events.

[^2]: **Notes:** Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group. a, cinobufotalin capsule; b, cinobufotalin injection; c, cinobufotalin tablet; S-1, Gimeracil and Oteracil Porassium Capsules.

[^3]: **Abbreviations:** ND, non determined; CF, Calcium folinate; SF, Sodium folinate; Fu, Fluorouracil; HCPT, Hydroxycamptothecin; FOLFOX, Oxaliplatin+CF+5-Fu; XELOX, Oxaliplatin+Capecitabine; EOF, Epirubicin+Oxaliplatin+5-Fu.

[^4]: **Notes:** Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group.

    **Abbreviations:** CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate.

[^5]: **Notes:** Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group.

[^6]: **Note:** Parameters discussed in over 8 papers were conducted bias analyses.

    **Abbreviations:** CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; QIR, quality of life improved rate.

[^7]: **Notes:** Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group.

    **Abbreviations:** ORR, overall response rate; DCR, disease control rate; FOLFOX, Oxaliplatin+Calcium folinate+5-Fluorouracil; XELOX, oxaliplatin+capecitabine; EOF, epirubicin+oxaliplatin+calcium folate+fluorouracil; RCT, randomized controlled trial.
